Osaic Holdings’s Cadrenal Therapeutics CVKD Stock Holding History

Osaic Holdings’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$324	Hold	300	–	–	﹤0.01%	7797
2026 Q2	$1K	Hold	300	–	–	﹤0.01%	7486
2026 Q1	$1.54K	Sell	300 -200	-40%	-$1.4K	﹤0.01%	7132
2025 Q4	$3.39K	Hold	500	–	–	﹤0.01%	6893
2025 Q3	$6.48K	Hold	500	–	–	﹤0.01%	6609
2025 Q2	$6.02K	Sell	500 -1,000	-67%	-$14.9K	﹤0.01%	6438
2025 Q1	$26.4K	Buy	1,500 +1,000	+200%	+$18.4K	﹤0.01%	5167
2024 Q4	$7.24K	Buy	+500	New	+$7.22K	﹤0.01%	5981

Other funds holding CVKD

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return

Vectors Research Management New York $362M AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Osaic Holdings's CVKD Position: Q3 2026 in Review

Osaic Holdings held its Cadrenal Therapeutics (CVKD) position steady in Q3 2026 at 300 shares worth $324. The position accounts for ﹤0.01% of the portfolio, ranked #7797.

Osaic Holdings first reported a position in CVKD in Q4 2024 and has held it in 8 quarters since. The position peaked at $26.4K in Q1 2025. 23 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

Osaic Holdings held 300 shares of Cadrenal Therapeutics worth $324 as of Q3 2026.
Osaic Holdings left its Cadrenal Therapeutics share count unchanged in Q3 2026.
Cadrenal Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q3 2026, its #7797 holding.
Osaic Holdings first reported a position in Cadrenal Therapeutics in Q4 2024 and has held it in 8 quarters since.
Osaic Holdings's Cadrenal Therapeutics position peaked at $26.4K in Q1 2025.
23 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on Osaic Holdings's 13F filing for Q3 2026, filed 12 Nov 2026.